Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATNFW OTCMKTS:FFNTF NASDAQ:LBPSW OTCMKTS:MEOBF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNFW180 Life Sciences$0.08+9.2%$0.13$0.00▼$0.62N/AN/A501,334 shs597,282 shsFFNTF4Front Ventures$0.00$0.00▼$0.07N/AN/A1.40 million shsN/ALBPSW4D pharma$0.00$0.04▼$1.29N/AN/A20,931 shsN/AMEOBFMesoblast$1.45-4.0%$1.34$0.81▼$5.34N/AN/A101,844 shs1,000 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNFW180 Life Sciences0.00%-57.77%-82.30%+828.05%+1,107.94%FFNTF4Front Ventures0.00%-87.50%-88.89%-80.00%-99.79%LBPSW4D pharma0.00%0.00%0.00%0.00%0.00%MEOBFMesoblast-3.97%-3.97%-5.84%+51.04%+129.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNFW180 Life Sciences$0.08+9.2%$0.13$0.00▼$0.62N/AN/A501,334 shs597,282 shsFFNTF4Front Ventures$0.00$0.00▼$0.07N/AN/A1.40 million shsN/ALBPSW4D pharma$0.00$0.04▼$1.29N/AN/A20,931 shsN/AMEOBFMesoblast$1.45-4.0%$1.34$0.81▼$5.34N/AN/A101,844 shs1,000 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNFW180 Life Sciences0.00%-57.77%-82.30%+828.05%+1,107.94%FFNTF4Front Ventures0.00%-87.50%-88.89%-80.00%-99.79%LBPSW4D pharma0.00%0.00%0.00%0.00%0.00%MEOBFMesoblast-3.97%-3.97%-5.84%+51.04%+129.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNFW180 Life Sciences 0.00N/AN/AN/AFFNTF4Front Ventures 0.00N/AN/AN/ALBPSW4D pharma 0.00N/AN/AN/AMEOBFMesoblast 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/AN/ALBPSW4D pharma$522KN/AN/AN/AN/AN/AMEOBFMesoblastN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNFW180 Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/A0.00N/AN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/A0.00N/AN/AN/AN/AN/AN/AMEOBFMesoblastN/A-$0.25N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNFW180 Life SciencesN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/AMEOBFMesoblastN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNFW180 Life SciencesN/AFFNTF4Front VenturesN/ALBPSW4D pharmaN/AMEOBFMesoblast27.35%Insider OwnershipCompanyInsider OwnershipATNFW180 Life SciencesN/AFFNTF4Front VenturesN/ALBPSW4D pharmaN/AMEOBFMesoblastN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNFW180 Life Sciences7N/AN/ANot OptionableFFNTF4Front Ventures460N/AN/ANot OptionableLBPSW4D pharmaN/AN/AN/ANot OptionableMEOBFMesoblast80N/AN/ANot OptionableMEOBF, ATNFW, LBPSW, and FFNTF HeadlinesRecent News About These CompaniesMesoblast Limited (MESO) Q4 2025 Earnings Call TranscriptAugust 29, 2025 | seekingalpha.comCanaccord Genuity Initiates Coverage of Mesoblast Limited (MESO) with Buy RatingAugust 17, 2025 | finance.yahoo.comMesoblast Limited (MESO) Launches First Cell Therapy for ChildrenJuly 28, 2025 | finance.yahoo.comJPMorgan Chase & Co. Reduces Stake in Mesoblast LimitedJuly 24, 2025 | tipranks.comMesoblast Limited Announces Quotation of New Securities on ASXJuly 14, 2025 | tipranks.comMesoblast Limited Announces Cessation of SecuritiesJuly 14, 2025 | tipranks.comJPMorgan Acquires Substantial Stake in Mesoblast LimitedJuly 6, 2025 | tipranks.comMesoblast Aligns with FDA for Revascor Biologics License ApplicationJune 30, 2025 | tipranks.comJPMorgan Chase & Co. Reduces Stake in Mesoblast LimitedJune 25, 2025 | tipranks.comJPMorgan Chase & Co. Ceases to be Substantial Holder in Mesoblast LimitedJune 15, 2025 | tipranks.comMesoblast Advances FDA Approvals for Revascor® and Ryoncil®June 11, 2025 | tipranks.comVanguard Group Acquires Substantial Stake in Mesoblast LimitedJune 5, 2025 | tipranks.comMesoblast Limited Announces Substantial Holding UpdateJune 3, 2025 | tipranks.comMesoblast Secures Seven-Year FDA Orphan-Drug Exclusivity for Ryoncil®May 14, 2025 | tipranks.comJPMorgan Acquires Substantial Stake in Mesoblast LimitedMay 13, 2025 | tipranks.comJPMorgan Ceases Substantial Holding in Mesoblast LimitedMay 8, 2025 | tipranks.comState Street Corporation Ceases Substantial Holding in Mesoblast LimitedMay 7, 2025 | tipranks.comMesoblast Expands U.S. Market with Ryoncil® Launch and Advances Other TherapiesApril 30, 2025 | tipranks.comMesoblast Limited Appoints New Director Lyn CobleyApril 28, 2025 | tipranks.comMesoblast Limited Announces Director’s Interest ChangeApril 23, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMEOBF, ATNFW, LBPSW, and FFNTF Company Descriptions180 Life Sciences NASDAQ:ATNFW$0.08 +0.01 (+9.18%) As of 09/12/2025180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.4Front Ventures OTCMKTS:FFNTF4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The company operates through THC Cannabis and CBD Wellness segments. THC Cannabis segment engages in the cultivation, production, manufacturing, and distribution of THC cannabis products to owned dispensaries and third party retailers; and provision of ancillary services. This segment sells equipment, supplies, and intellectual property to cannabis producers; and leases real estate properties. The CBD Wellness segment sells non-THC hemp derived products. In addition, it operates dispensaries in the Massachusetts, Illinois, and Michigan primarily under the MISSION brand name. 4Front Ventures Corp. was founded in 2011 and is based in Phoenix, Arizona.4D pharma NASDAQ:LBPSW4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.Mesoblast OTCMKTS:MEOBF$1.45 -0.06 (-3.97%) As of 09/15/2025 10:57 AM EasternMesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
